Phentermine + topiramate

Phentermine + topiramate has been studied in 38 papers since 2017: 1 trial and 9 observational studies in people, 27 reviews; 16 in the past year. It is an approved medicine. The newest paper, Nov 2, 2026: “Weight-Loss-Enriched Reverse Cardiac Remodeling After Semaglutide and Tirzepatide Initiation on Longitudinal Echocardiography”.

InterventionApproved 2012

38 papers study it13 more mention it8 findingsUpdated

PubChemPubChemChEBIChEBI

3 new papers in 30 daysSee all 51 papers on phentermine + topiramate

At a glance

Independent labs found the same change in people. 3 independent labs in 2 countries; 23 trials, none about aging, 4 with no results posted.

“At 12 months, weight loss was 15.32 kg versus 5.85 kg, respectively (mean difference -9.48 kg; p < 0.001).”
Addition of Phentermine-Topiramate to a Digitally Enhanced Lifestyle Intervention: A Double-Blind Randomized Clinical TrialObesity (Silver Spring, Md.)2026doi:10.1002/oby.70108

None of its findings points the other way.

Humans: replicated by independent labs. Cells, worms or flies and mice: nothing yet.
  • 3 independent labs in 2 countries
  • 23 trials, none about aging, 4 with no results posted
  • Funders: VIVUS and 1 more
  • 2 of 7 findings with company ties
  • 10 of 23 trials sponsored by its developers
  • Human trial1
  • Humans9
  • In silico1

Studies in people

1 study gave phentermine + topiramate to people and measured what changed.

What changedDesignPeopleSource

down: Decreases body weight-9.48 kg

down: Decreases Atherosclerotic Cardiovascular Disease Risk Score-3.35%

Randomized trial12 months80 peoplePatient cohortsObesity (Silver Spring, Md.), Jan 21, 2026

What did studies of phentermine + topiramate find?

6

Studies of phentermine + topiramate measured 6 outcomes; the most studied is body weight (3 studies).

Body weight

downin humans3−7.9%

3 studies
  1. Phentermine + topiramate decreases body weight in humans (-9.48 kg).

    “At 12 months, weight loss was 15.32 kg versus 5.85 kg, respectively (mean difference -9.48 kg; p < 0.001).”

    Human trial12 monthsn = 80

    Addition of Phentermine-Topiramate to a Digitally Enhanced Lifestyle Intervention: A Double-Blind Randomized Clinical Trial

    Obesity (Silver Spring, Md.)

  2. Phentermine + topiramate is linked with lower body weight in humans (-1.59 percentage points).

    “Phentermine/topiramate showed greater mean percentage weight loss at 6 months than orlistat (adjusted difference, -1.59 percentage points; p < 0.001)”

    Humans6 months

    Comparative effectiveness of long-term anti-obesity medications in routine clinical practice: a retrospective cohort study using real-world data

    Translational and clinical pharmacology

  3. Phentermine + topiramate is linked with lower body weight in humans (-7.9%).

    “At 5-6 months, the mean weight reduction was 7.9%”

    Humans5-6 monthsn = 1,839

    Efficacy of phentermine/topiramate extended release in weight management and metabolic profiles: A multicentre study in South Korea

    Diabetes, obesity & metabolism

Atherosclerotic Cardiovascular Disease Risk Score

downin humans1−3.4%

1 study
  1. Phentermine + topiramate decreases Atherosclerotic Cardiovascular Disease Risk Score in humans (-3.35%).

    “Participants receiving phentermine-topiramate-ER experienced a 3.35% reduction in the estimated atherosclerotic CVD risk compared to baseline (p = 0.004).”

    Human trial12 monthsn = 42

    Addition of Phentermine-Topiramate to a Digitally Enhanced Lifestyle Intervention: A Double-Blind Randomized Clinical Trial

    Obesity (Silver Spring, Md.)

More on Atherosclerotic Cardiovascular Disease Risk Score

Systolic blood pressure

downin humans1

1 study
  1. Phentermine + topiramate is linked with lower systolic blood pressure in humans (-6 ± 15 mmHg, p < 0.001).

    “systolic blood pressure by 6 ± 15 mmHg (all p < 0.001)”

    Humans5-6 months

    Efficacy of phentermine/topiramate extended release in weight management and metabolic profiles: A multicentre study in South Korea

    Diabetes, obesity & metabolism

More on Systolic blood pressure

Low-density lipoprotein cholesterol

downin humans1

1 study
  1. Phentermine + topiramate is linked with lower low-density lipoprotein cholesterol in humans (-10 ± 32 mg/dL, p < 0.001).

    “low-density lipoprotein (LDL) cholesterol by 10 ± 32 mg/dL”

    Humans5-6 months

    Efficacy of phentermine/topiramate extended release in weight management and metabolic profiles: A multicentre study in South Korea

    Diabetes, obesity & metabolism

More on Low-density lipoprotein cholesterol

HbA1c

downin humans1

1 study
  1. Phentermine + topiramate is linked with lower HbA1c in humans (-0.4 ± 0.9%, p < 0.001).

    “the HbA1c decreased by 0.4 ± 0.9%”

    Humans5-6 months

    Efficacy of phentermine/topiramate extended release in weight management and metabolic profiles: A multicentre study in South Korea

    Diabetes, obesity & metabolism

More on HbA1c

Treatment cost

downin silico1

1 study
  1. Phentermine + topiramate decreases treatment cost in silico (compared with other anti-obesity medications) (nearly identical QALYs to other agents).

    “Compared to other AOM, PpT was lowest cost treatment with nearly identical QALYs with other agents.”

    In silicocompared with other anti-obesity medications

    Cost-effectiveness analysis of five anti-obesity medications from a US payer's perspective

    Nutrition, metabolism, and cardiovascular diseases : NMCD

Has phentermine + topiramate been tested in people?

0 of 23 about aging

Yes: 1 trial and 9 observational studies in people have been published, and 20 trials are registered.

Approved

  • FDA Qsymia

    Jul 17, 2012Obesity, Overweight, excess body weight

Repurposing

All 10

In trials

  • Hypothalamic tumor

    Phase 2Active, not recruiting1 trial

Stopped

  • NCT04531176TerminatedObesity

    After an unplanned yet IRB approved interim analysis, it was found that there was not a significant difference between the 3 arms of the study. The study was closed due to futility. All Patients are off study and this study will not resume.

Who is developing phentermine + topiramate?

1 company: VIVUS.

Companies

Trial sponsors

Latest

Dec 2025: 2Jan 2026: 4Feb 2026: 3Mar 2026: 2Apr 2026: 0May 2026: 1Jun 2026: 2Jul 2026: 0Aug 2026: 0Sep 2026: 2Oct 2026: 3Nov 2026: 120 papers in 12 months

See all 51 papers on phentermine + topiramate